Prescribing Patterns for Sodium-Glucose Cotransporter 2 Inhibitors: A Survey of Nephrologists.

Diabetes mellitus is a leading cause of end-stage kidney disease worldwide. Thirty percent of adults with diabetes have chronic kidney disease (CKD) in the United States.1 Multiple randomized controlled trials have shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) slow the progression of CKD and prolong the time to dialysis in patients with diabetic CKD and nondiabetic CKD.2,3 Despite the robust evidence from randomized controlled trials, the approval by the US Food and Drug Administration, and the strong recommendation by international organizations such as Kidney Disease Improving Global Outcomes, fewer than 10% of patients with an indication for SGLT2i are prescribed this class of medication.